Cannabis Science, Inc, together with its subsidiaries, develops, produces, and commercializes phytocannabinoid-based pharmaceutical products primarily in the United States. The company is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. Its drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryCannabis
SectorMedical
Phone+1-888-8890888
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cannabis Science (OTCMKTS:CBIS) Frequently Asked Questions
What is Cannabis Science's stock symbol?
Cannabis Science trades on the OTCMKTS under the ticker symbol "CBIS."
How were Cannabis Science's earnings last quarter?
Cannabis Science Inc (OTCMKTS:CBIS) posted its quarterly earnings results on Tuesday, July, 28th. The company reported $0.00 earnings per share for the quarter. View Cannabis Science's Earnings History.
Has Cannabis Science been receiving favorable news coverage?
News headlines about CBIS stock have trended positive on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cannabis Science earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Cannabis Science.
Who are some of Cannabis Science's key competitors?
Some companies that are related to Cannabis Science include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Biome Grow (BIO), Blueberries Medical (BBM), Canbiola (CANB), Cannara Biotech (LOVE), Cansortium (CNTMF), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF) and CLS Holdings USA (CLSH).
What other stocks do shareholders of Cannabis Science own?
Who are Cannabis Science's key executives?
Cannabis Science's management team includes the folowing people:
- Mr. Raymond C. Dabney, Co-Founder, Chairman, CEO & Pres (Age 54)
- Mr. Benjamin C. K. Tam, CFO, Sec. & Director (Age 67)
- Mr. Robert James Kane, COO & Director (Age 43)
- Mr. Mario Lap, Pres of European Operations & Director (Age 67)
- Mr. Bret Bogue, Director of Horticulture and Head of R&D
How do I buy shares of Cannabis Science?
Shares of CBIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cannabis Science's stock price today?
One share of CBIS stock can currently be purchased for approximately $0.0233.
What is Cannabis Science's official website?
How can I contact Cannabis Science?
Cannabis Science's mailing address is 19800 Macarthur Blvd Ste 300, IRVINE, CA 92612-2479, United States. The company can be reached via phone at +1-888-8890888.
MarketBeat Community Rating for Cannabis Science (OTCMKTS CBIS)
MarketBeat's community ratings are surveys of what our community members think about Cannabis Science and other stocks. Vote "Outperform" if you believe CBIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
